°Ù¼ÃÉñÖݹ«²¼2019ÄêµÚËļ¾¶ÈºÍÈ«Äê²ÆÎñÒµ¼¨

·¢²¼Ê±¼ä£º2020-03-03 15:36:46 À´Ô´£º
ÃÀ¹úÂéÊ¡½£ÇźÍÖйú±±¾©2020Äê3Ô 3ÈÕ /ÃÀͨÉç/ -- °Ù¼ÃÉñÖÝ£¨ÄÉ˹´ï¿Ë´úÂ룺BGNE£»Ïã¸ÛÁª½»Ëù´úÂ룺06160£©ÊÇÒ»¼Ò´¦ÓÚÉÌÒµ½×¶ÎµÄÉúÎïÒ½Ò©¹«Ë¾£¬×¨×¢ÓÚÓÃÓÚ°©Ö¢ÖÎÁƵĴ´ÐÂÐÍ·Ö×Ó°ÐÏòºÍÃâÒßÖ×ÁöÒ©ÎïµÄ¿ª·¢ºÍÉÌÒµ»¯¡£¹«Ë¾½ñÌ칫²¼½üÆÚÒµÎñÁÁµã¡¢Ô¤¼ÆÀï³Ì±®Ê¼þ£¬ÒÔ¼°2019ÄêµÚËļ¾¶ÈºÍÈ«Äê²ÆÎñÒµ¼¨¡£

°Ù¼ÃÉñÖÝ´´Ê¼ÈË¡¢Ê×ϯִÐйټ涭ʳ¤Å·À×Ç¿ÏÈÉú±íʾ£º¡°×Ô2010ÄêºÍÍõÏþ¶«ÔºÊ¿Ò»Æð³ÉÁ¢°Ù¼ÃÉñÖÝÒÔÀ´£¬ÎÒÃÇÒѾ­×ß¹ýÁËÊ®¸öÄêÍ·¡£×î½üÎÒÃǹ«²¼ÁËÁ½Ïî3ÆÚÁÙ´²ÊÔÑéÊý¾Ý¡¢BRUKINSA!"£¨Ôó²¼ÌæÄᣩºÍ°ÙÔó°²®ÔÚÃÀ¹úºÍÖйú·Ö±ð»ñÅú¡¢Óë°²½ø¹«Ë¾½¨Á¢µÄºÏ×÷¹ØÏµÕýʽÉúЧ£¬ÎªÐµÄÒ»Ä꿪Á˸öºÃÍ·¡£ÎÒÃǽ«¾Í°²½øµÄÈý¿îÉÌÒµ½×¶ÎÒ©Î↑չÉÌÒµ»¯·¢Õ¹£¬²¢¶ÔÆä20¿îºòѡҩÎï½øÐÐÁÙ´²¿ª·¢¡£ÎÒÃÇÏàÐÅÊ®ÖÜÄêµÄ°Ù¼ÃÉñÖÝ»á³ÖÐø2019µÄÇ¿¾¢·¢Õ¹ÊÆÍ·£¬²»¶Ï½ø²½¡£Î´À´µÄÁ½Ä꣬ÎÒÃÇÔ¤¼Æ½«Íƽø¶àÖÁ°Ë¿îÒ©ÎïÉÏÊв¢¼ÌÐøÍÆ¶¯ÁÙ´²¿ª·¢£¬ÓÐÍû¹«²¼10¶àÏî3ÆÚ»òDZÔÚµÄÖ§³Ö×¢²áµÄÁÙ´²ÊÔÑé½á¹û¡£ÎÒÃÇÒ²¼ÌÐøÍÆ½ø¹«Ë¾ÔçÆÚÒ©Îï¹ÜÏߣ¬ÆäÖжà¿î×ÔÖ÷Ñз¢»òÊÚȨÒý½øÒ©Îï¼´½«½øÈëÁÙ´²¿ª·¢½×¶Î»ò¹«²¼¸ÅÄîÑéÖ¤Êý¾Ý¡£¡±

°Ù¼ÃÉñÖÝÖйúÇø×ܾ­Àí¼æ¹«Ë¾×ܲÃÎâÏþ±õ²©Ê¿±íʾ£º¡°¾¡¹Üйڲ¡¶¾ÒßÇé¶ÔÎÒÃÇÔÚÖйúµÄÒµÎñ´øÀ´ÁËÒ»¶¨µÄÌôÕ½£¬ÎÒÃǵÄÍŶӼÌÐøÍÆ½ø¹«Ë¾µÄ¸÷ÏîÒµÎñ£¬Îª»¼Õß·þÎñ¡£ÒßÇ龯±¨À­ÏìÖ®ºó£¬ÎÒÃÇÁ¢¿Ì²ÉÈ¡Á˰²È«´ëÊ©ÒÔ±£»¤ÔÚÎ人ºÍÆäËûµØÇøµÄÔ±¹¤£¬ÎÒÃÇÒ²ºÜÐÀοµØ±¨¸æËùÓаټÃÉñÖݵÄÔ±¹¤Ä¿Ç°¶¼°²È«¡£´ËÍ⣬°Ù¼ÃÉñÖÝÊǵÚÒ»Åú²É¹º°²È«·À»¤É豸µÄÒ½Ò©¹«Ë¾²¢½«Îï×ÊÔ˵ÖÒßÇéÖØÔÖÇøµÄ¸÷´óÒ½Ôº¡£ËäÈ»ÎÒÃÇÔ¤¼Æ´Ë´ÎÒßÇ齫¶ÔÎÒÃÇÔÚÖйúµÄ¶àÏîÒµÎñ²úÉúÓ°Ï죬ÎÒÃÇÈÔÈ»³¯×ŰÙÔó°²®ÔÚ½ñÄêµÚÒ»¼¾¶ÈÉÌÒµ»¯ÉÏÊеÄÄ¿±êŬÁ¦¡£¡±

½üÆÚÒµÎñÁÁµã

ÉÌÒµÔËÓª

  • BRUKINSA!"£¨Ôó²¼ÌæÄᣩ»ñµÃÃÀ¹úʳƷҩƷ¹ÜÀí¾Ö£¨FDA£©¼ÓËÙÅú×¼ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÁÉÙÒ»ÏîÁÆ·¨µÄ³ÉÄêÌ×ϸ°ûÁܰÍÁö£¨MCL£©»¼Õߣ¬²¢ÓÚ»ñÅúÒ»ÖÜÖ®ÄÚÉÌÒµÉÏÊÐ
  • °ÙÔó°²®£¨ÌæÀ×ÀûÖéµ¥¿¹×¢ÉäÒº£©»ñµÃ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼ÓÃÓÚÖÎÁÆÖÁÉÙ¾­¹ý¶þÏßϵͳ»¯ÁƵľ­µäÐÍ»ôÆæ½ðÁܰÍÁö£¨cHL£©»¼Õߣ¬¼Æ»®ÓÚ±¾ÔÂʵÏÖÉÌÒµ»¯ÉÏÊÐ
  • ½ØÖÁ2019Äê12ÔÂ31ÈÕµÄÄê¶È²úÆ·ÊÕÈëΪ2.226ÒÚÃÀÔª £¬Ö÷ÒªÀ´×ÔABRAXANE®¡¢Èð¸´ÃÀ®ºÍά´ïɯ®ÔÚÖйúÏúÊÛ´øÀ´µÄÊÕÈ룬Ïà±È½Ï2018ÄêͬÆÚµÄ²úÆ·ÊÕÈ룬ʵÏÖÁË70.1%µÄÔö¼Ó¡£½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈÊÕÈëΪ5689ÍòÃÀÔª¡£°Ù¼ÃÉñÖÝÔÚлùÎïÁ÷ÓÐÏÞÔðÈι«Ë¾£¨ÊôÓÚ°ÙʱÃÀÊ©¹ó±¦£©µÄ¶À¼ÒÊÚȨÏ£¬ÔÚ»ªÏúÊÛABRAXANE®¡¢Èð¸´ÃÀ®ºÍά´ïɯ®
  • ÔÚÖйúµÝ½»ÁËÈð¸´ÃÀ®£¨À´ÄǶȰ·£©ÁªºÏÀûÍ×Îôµ¥¿¹ÓÃÓÚÖÎÁƸ´·¢»òÄÑÖÎÐÔ£¨R/R£©¶èÐÔÁܰÍÁö£¨ÂËÅÝÐÍÁܰÍÁö»ò±ßÔµÇøÁܰÍÁö£©»¼ÕߵĽø¿ÚÒ©Æ·ÐÂÊÊÓ¦Ö¢ÉÏÊÐÉêÇ루sNDA£©£¬¸ÃsNDAÒѱ»ÊÜÀí±»ÄÉÈëÓÅÏÈÉóÆÀ
  • ABRAXANE®±»ÄÉÈë¹ú¼ÒÒ½ÁƱ£ÕϾÖÒ©Æ·¼¯ÖвɹºÃûµ¥£¬ÓÚ2020ÄêµÚ¶þ¼¾¶ÈÕýʽÉúЧ

ÁÙ´²ÏîÄ¿

BRUKINSA!"£¨Ôó²¼ÌæÄᣩ£¬Ò»¿îÉè¼ÆÖ¼ÔÚ×î´ó»¯²¼Â³¶ÙÀÒ°±Ëἤø£¨BTK£©Õ¼ÓÐÂÊ¡¢×îС»¯ÍѰÐЧӦµÄС·Ö×ÓÒÖÖÆ¼Á£»ÔÚÃÀ¹úÒÑ»ñÅú

  • ¹«²¼BRUKINSA!"£¨Ôó²¼ÌæÄᣩ¶Ô±ÈÒÁ²¼ÌæÄáÓÃÓÚÖÎÁÆ»ªÊϾÞÇòµ°°×Ѫ֢£¨WM£©»¼ÕßµÄASPEN 3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03053440£©½á¹û¡£¾¡¹Ü¸ÃÊÔÑéµÄÖ÷ÒªÖÕµãÉî¶È»º½â£¨·Ç³£ºÃµÄ²¿·Ö»º½â[VGPR]»ò¸üºÃ£©Î´ÄÜ´ïµ½ÓÐͳ¼ÆÑ§ÒâÒåµÄÓÅЧÐÔ£¬Ïà±ÈÒÁ²¼ÌæÄᣬÔó²¼ÌæÄáÈ¡µÃÁ˸ü¸ßµÄVGPRÂÊ£¨28.4%£¬¶Ô±ÈËùÓнÓÊÜÖÎÁÆ»¼ÕßÖеÄ19.2%£©¡£Í¬Ê±Ôó²¼ÌæÄáÔÚ°²È«ÐÔºÍÄÍÊÜÐÔÉ϶ԱÈÒÁ²¼ÌæÄáÒ²ÓÐÏÔÖø¸ÄÉÆ¡£ASPENÊÇÆù½ñΪֹÔÚWM»¼ÕßÖпªÕ¹µÄ×î´ó¹æÄ£µÄ3ÆÚÁÙ´²ÊÔÑ飬ҲÊÇBTKÒÖÖÆ¼Á¶Ô±ÈÊÔÑéµÄÊ×´ÎÊý¾Ý¹«²¼
  • Íê³ÉÁËÓÃÓÚÖÎÁÆR/R±ßÔµÇøÁܰÍÁö£¨MZL£©»¼ÕßµÄMAGNOLIA 2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03846427£©µÄ»¼ÕßÈë×é
  • ÔÚµÚ61½ìÃÀ¹úѪҺѧЭ»á£¨ASH£©Äê»áÉϹ«²¼ÁËÒÔÏÂÊý¾Ý£º
    • ÔÚÒ»Ïî¿ÚÍ·±¨¸æÖÐÊ״ι«²¼ÁËÓÃÓÚÖÎÁÆÈ±Ê§È¾É«Ìå17pµÄ³õÖΣ¨TN£©ÂýÐÔÁܰÍϸ°û°×Ѫ²¡£¨CLL£©»òСÁܰÍϸ°ûÁܰͰ©£¨SLL£©»¼ÕßµÄSEQUOIAÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03336333£©C×éÊý¾Ý
    • ÔÚÒ»Ïî¿ÚÍ·±¨¸æÖй«²¼ÁËÓÃÓÚÖÎÁÆCLL»òSLL»¼ÕßµÄ1/2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT02343120£©µÄ¸üÐÂÊý¾Ý
    • ÔÚÒ»Ï±¨Õ¹Ê¾Öй«²¼ÁËÔó²¼ÌæÄáÁªºÏ°ÙÔó°²®ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÎÁƵÄBϸ°û¶ñÐÔÁܰÍÁö»¼ÕßµÄ1bÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT02795182£©µÄ¸üÐÂÊý¾Ý
  • ÔÚÈÕ±¾Æô¶¯ÁËÔó²¼ÌæÄáÓÃÓÚÖÎÁƳÉÊìBϸ°û¶ñÐÔÖ×Áö»¼ÕßµÄ1/2ÆÚÁÙ´²ÊÔÑé

Ôó²¼ÌæÄáÔ¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020ÄêÉϰëÄêÔÚÖйú»ñÅúÓÃÓÚÖÎÁÆR/R MCL»¼ÕßÒÔ¼°R/R CLL»òSLL»¼Õß
  • ×îÔçÓÚ2020ÄêϰëÄ깫²¼Ôó²¼ÌæÄá¶Ô±È±½´ïĪ˾͡ÁªºÏÀûÍ×Îôµ¥¿¹ÓÃÓÚÖÎÁÆTN CLL»òSLL»¼ÕßµÄSEQUOIAÁÙ´²ÊÔÑéµÄÖ÷ÒªÊý¾Ý
  • ÓÚ2020ÄêÔÚÖйúµÝ½»ÓÃÓÚÖÎÁÆWM»¼ÕßµÄsNDA
  • ÓëFDAºÍÅ·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©¾ÍASPENÊý¾Ý¿ªÕ¹¶Ô»°£¬²¢ÔÚ2020ÄêµÄÒ»³¡Ö÷Ҫҽѧ»áÒéÉϹ«²¼ASPEN 3ÆÚÁÙ´²ÊÔÑéÊý¾Ý
  • ÓÚ2020ÄêÍê³ÉÔó²¼ÌæÄá¶Ô±ÈÒÁ²¼ÌæÄáÓÃÓÚÖÎÁÆR/R CLL»òSLL»¼ÕßµÄALPINE 3ÆÚÁÙ´²ÊÔÑéÀ©Õ¹ºóµÄ»¼ÕßÈë×é

°ÙÔó°²®£¨ÌæÀ×ÀûÖéµ¥¿¹×¢ÉäÒº£©£¬Ò»¿îÉè¼ÆÖ¼ÔÚ±ÜÃâÓë¾ÞÊÉϸ°ûÖÐFcÊÜÌå½áºÏ¡¢Õë¶ÔÃâÒß¼ì²éµãÊÜÌåPD-1µÄÈËÔ´»¯IgG4µ¥¿Ë¡¿¹Ìå

  • ¹«²¼ÌæÀ×ÀûÖéµ¥¿¹ÁªºÏ»¯ÁÆÓÃÓÚÖÎÁÆÒ»ÏßÁÛ×´·ÇСϸ°û·Î°©£¨NSCLC£©»¼ÕߵĹؼü3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03594747£©ÔÚÔ¤Ïȼƻ®µÄÖÐÆÚ·ÖÎöÖУ¬¾­¶ÀÁ¢ÆÀÉóίԱ»á£¨IRC£©ÆÀ¹À£¬´ïµ½Ìá¸ßÎÞ½øÕ¹Éú´æÆÚ£¨PFS£©ÕâÒ»ÊÔÑéÖ÷ÒªÖյ㡣Á½×é°ÙÔó°²®ÊÔÑé×éµÄ°²È«ÐÔÊý¾ÝÓë¸÷ÊÔÑéÖÎÁÆÒÑÖªµÄ·çÏÕÏà·û£¬Î´³öÏÖÐµİ²È«¾¯Ê¾
  • »ñµÃÁËFDAÊÚÓèµÄÔÚ¸Îϸ°û°©£¨HCC£©ºÍʳ¹ÜÁÛ״ϸ°û°©£¨ESCC£©Á½ÏîÊÊÓ¦Ö¢ÖеŶùÒ©ÎïÈ϶¨
  • ÔÚ2019ÄêÅ·ÖÞÖ×ÁöÄÚ¿ÆÑ§»á£¨ESMO£©ÑÇÖÞ´ó»áÉϹ«²¼Á˰ÙÔó°²®ÁªºÏ»¯ÁÆÓÃÓÚÖÎÁÆÓÃÓÚÖÎÁÆÎ¸/θʳ¹Ü½áºÏ²¿£¨G/GEJ£©ÏÙ°©»¼ÕßÒÔ¼°ESCC»¼ÕßµÄ2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03469557£©µÄ¸üÐÂÊý¾Ý

°ÙÔó°²®Ô¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020ÄêÔÚÖйú»ñÅúÓÃÓÚÖÎÁƾֲ¿ÍíÆÚ»ò×ªÒÆÐÔÄò·ÉÏÆ¤°©£¨UC£©»¼Õß
  • ÓÚ2020ÄêÔÚÖйúµÝ½»ÓÃÓÚÖÎÁÆÒ»ÏßÁÛ×´NSCLC»¼ÕßµÄsNDA
  • ÓÚ2020Äê¾Í°ÙÔó°²®ÓÃÓÚÖÎÁƶþ»òÈýÏßHCC»¼ÕßµÄÈ«Çò2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03419897£©µÄ³õ²½½á¹ûÓëÒ©Æ·¼à¹Ü»ú¹¹½øÐйµÍ¨
  • ÓÚ2020Ä깫²¼ÔÚÖйú¿ªÕ¹µÄ°ÙÔó°²®ÁªºÏ»¯ÁƶԱȻ¯ÁÆÓÃÓÚÖÎÁÆÒ»Ïß·ÇÁÛ×´NSCLC»¼ÕßµÄ3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03663205£©µÄÖ÷ÒªÊý¾Ý
  • ÓÚ2020ÄêÍê³ÉÔÚÖйú¿ªÕ¹µÄÓÃÓÚÖÎÁÆ´íÅäÐÞ¸´È±ÏÝ£¨dMMR£©»ò¸ß΢ÎÀÐDz»Îȶ¨£¨MSI-H£©ÊµÌåÁö»¼ÕߵĹؼüÐÔ2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03736889£©µÄ»¼ÕßÈë×é
  • ÓÚ2020Äê³õÍê³É°ÙÔó°²®¶Ô±È¶àÎ÷ËûÈüÓÃÓÚÖÎÁƶþ»òÈýÏßNSCLC»¼ÕßµÄ3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03358875£©È«Çò²¿·ÖµÄ»¼ÕßÈë×飬ÒÔ¼°°ÙÔó°²®¶Ô±È»¯ÁÆÓÃÓÚÖÎÁƶþÏßÍíÆÚESCC»¼ÕßµÄÈ«Çò3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03430843£©»¼ÕßÈë×é²¢ÓÚ2020Äê»ò2021Äê³õ¹«²¼ÕâÁ½ÏîÊÔÑéµÄÖ÷Òª½á¹û¡£

Pamiparib£¬Ò»¿îÔÚÑиßÑ¡ÔñÐÔPARP1ºÍPARP2С·Ö×ÓÒÖÖÆ¼Á

  • Ðû²¼Á˽«pamiparib¶Ô±È°²Î¿¼Á×÷ΪÔÚÒÔ²¬ÀàÒ©ÎïΪ»ù´¡µÄÒ»Ïß»¯Áƺó²úÉú»º½âµÄ²»¿ÉÊÖÊõµÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔθ°©»¼Õßά³ÖÖÎÁƵÄÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03427814£»»òBGB-290-303£©ÓÉ3ÆÚתΪ2ÆÚµÄ¼Æ»®¡£¹«Ë¾»¹½«¶Ô2ÆÚÁÙ´²ÊÔÑéÊý¾Ý½øÐзÖÎöÒÔÆÀ¹ÀpamiparibÔÚÕâÏîÊÊÓ¦ÖеÄDZÁ¦£¬ÒÔ¼°×÷Ϊµ¥Ò©ÁÆ·¨»òÓëÆäËûÁÆ·¨½áºÏµÄDZÔÚ¿ª·¢¼Æ»®¡£

PamiparibÔ¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020Äê¾ÍÔÚÖйú¿ªÕ¹µÄÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýÖÎÁƵÄÈýÏß»òÒÔÉÏЯ´øBRCA1/2Í»±äµÄÍíÆÚÂѳ²°©£¨OC£©»¼ÕߵĹؼüÐÔ2ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03333915£©µÄ³õ²½½á¹ûÓëÒ©Æ·¼à¹Ü»ú¹¹½øÐйµÍ¨£¬²¢¿ÉÄÜÔÚÖйúµÝ½»Õë¶Ô¸ÃÊÊÓ¦Ö¢µÄÐÂÒ©ÉÏÊÐÉêÇ루NDA£©
  • ÓÚ2020Äê»ò2021ÄêÉϰëÄ깫²¼pamiparib×÷Ϊ²¬Ãô¸Ð¸´·¢ÐÔOC»¼Õßά³ÖÖÎÁƵÄ3ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03519230£©µÄÖ÷Òª½á¹û
  • ÓÚ2020Ä깫²¼pamiparibÁªºÏ°ÙÔó°²®ÓÃÓÚÖÎÁÆÍíÆÚʵÌåÁö»¼ÕßµÄ1ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT02660034£©µÄ¸üнá¹û

Sitravatinib£¬Ò»¿îÔÚÑеÄÀÒ°±ËἤøÒÖÖÆ¼Á£¬¿ÉÓÐЧÒÖÖÆÊÜÌåÀÒ°±Ëἤø£¨RTKs£©£¬ÆäÖаüÀ¨ TAM¼Ò×åÊÜÌ壨TYRO3¡¢Axl¡¢MER£©ºÍ split¼Ò×åÊÜÌ壨VEGFR2¡¢KIT£©¼° RET£¬ÓÉ Mirati TherapeuticsÊÚȨÔÚÑÇÖÞ£¨ÈÕ±¾³ýÍ⣩¡¢°Ä´óÀûÑǺÍÐÂÎ÷À¼µÄ¿ª·¢

  • ÔÚ2019Äê12Ô¾ٰìµÄESMOÖ×ÁöÃâÒßѧ»áÉϵÄÒ»Ïî¿ÚÍ·±¨¸æÖй«²¼ÁËsitravatinibÁªºÏ°ÙÔó°²®ÓÃÓÚÖÎÁƲ¬ÀàÄÍÒ©OC»¼ÕßµÄ1bÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT03666143£©Êý¾Ý

SitravatinibÔ¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020ÄêÔÚÒ»³¡Ò½Ñ§»áÒéÉϹ«²¼sitravatinibÁªºÏ°ÙÔó°²®µÄ1ÆÚÁÙ´²ÊÔÑéÊý¾Ý

ZW25£¬Ò»¿îÔÚÑÐAzymetric!"Ë«ÌØÒìÐÔ¿¹Ì壬ÓëZymeworksºÏ×÷¿ªÕ¹2ÆÚÁÙ´²¿ª·¢

ZW25Ô¤¼ÆÀï³Ì±®Ê¼þ

  • Ϊ¼Æ»®ÖеÄÕë¶Ô¸´·¢ÐÔHER2ÑôÐÔµ¨µÀ°©£¨2020Ä꣩ÒÔ¼°Õë¶ÔÒ»ÏßHER2ÑôÐÔθʳ¹ÜÏÙ°©£¨2020ÄêÄ©ºÍ2021Äê³õ£©µÄ×¢²áÐÔÊÔÑéµÄÁÙ´²¿ª·¢ºÍ»¼ÕßÈë×éÌṩ֧³Ö
  • ÓÚ2020Äê³õÆô¶¯Ò»Ïî1b/2ÆÚÁÙ´²ÊÔÑéÓÃÓÚÆÀ¹ÀZW25ÁªºÏ»¯ÁƺͰÙÔó°²®¶Ô±ÈZW25ÁªºÏ»¯ÁÆÖÎÁÆÍíÆÚHER2ÑôÐÔÈéÏÙ°©»òG/GEJÏÙ°©»¼Õß

Lifirafenib£¬Ò»¿îÔÚÑÐRAF¶þ¾ÛÌåÒÖÖÆ¼Á

LifirafenibÔ¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020ÄêÔÚͬÐÐÆÀÒéÆÚ¿¯ÉÏ·¢±í1ÆÚÊý¾Ý

BGB-A1217£¬Ò»¿îÔÚÑÐTIGITµ¥¿Ë¡¿¹Ìå

BGB-A1217Ô¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020Äê»ò2021Äê³õ¹«²¼1ÆÚÁÙ´²ÊÔÑé

BGB-A445£¬Ò»¿îÔÚÑзÇÅäλÌ忹OX40¼¤¶¯ÐÔµ¥¿Ë¡¿¹Ìå

  • Æô¶¯ÁËBGB-A445×÷Ϊµ¥Ò©»òÁªºÏ°ÙÔó°²®ÓÃÓÚÖÎÁÆÍíÆÚʵÌåÁö»¼ÕßµÄ1ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT04215978£©

BGB-3245£¬Ò»¿îÔÚÁÙ´²Ç°Ñо¿ÖÐչʾÁ˶Կ¹µ¥¾ÛÌåºÍ¶þ¾ÛÌåB-RAFÍ»±äÐÍ»îÐÔµÄÔÚÑÐB-RAFÒÖÖÆ¼Á£¬Ä¿Ç°ÓɰټÃÉñÖݺÍSpringWorks Therapeutics¹²Í¬³ÖÓеÄMapKure½øÐпª·¢

  • Æô¶¯ÁËÓÃÓÚÖÎÁÆÐ¯´øÌض¨v-RAFÊóÈâÁö²¡¶¾°©»ùÒòͬԴÎïB£¨B-RAF£©»ùÒòÍ»±äÐÍÍíÆÚ»ò¸´·¢ÐÔ»¼ÕßµÄ1ÆÚÁÙ´²ÊÔÑ飨clinicaltrials.govµÇ¼ÇºÅ£ºNCT04249843£©

BGB-11417£¬Ò»¿îÔÚÑÐBcl-2С·Ö×ÓÒÖÖÆ¼Á

  • ÔÚ°Ä´óÀûÑǺÍÃÀ¹úÆô¶¯ÁËÓÃÓÚÖÎÁƳÉÊìBϸ°û¶ñÐÔÖ×Áö»¼ÕßµÄ1ÆÚÁÙ´²ÊÔÑéµÄ°²ÅÅ

BGB-11417Ô¤¼ÆÀï³Ì±®Ê¼þ

  • ÓÚ2020ÄêµÚÒ»¼¾¶È»òµÚ¶þ¼¾¶È³õ¿ªÕ¹ÓÃÓÚÖÎÁƳÉÊìBϸ°û¶ñÐÔÖ×Áö»¼ÕßµÄ1ÆÚÁÙ´²ÊÔÑ黼ÕßÈë×é

Éú²ú»ùµØ

  • ¹ãÖÝÉúÎïÒ©Æ·Éú²ú»ùµØÓÚ2019Äê12Ô»ñµÃÒ©ÎïÉú²úÐí¿ÉÖ¤
  • Æô¶¯Á˰ÙÔó°²®Éú²ú³ÌÐòÑéÖ¤
  • ¿ªÆô¹ãÖÝÉúÎïÒ©Æ·Éú²ú»ùµØ¶þÆÚ¹¤³ÌÒÔÀ©´óÉú²úÄÜÁ¦£¬Ô¤¼ÆÓÚ2020Äêµ×֮ǰÍê³É

¹«Ë¾·¢Õ¹

  • Ðû²¼ÁËÓë°²½ø¹«Ë¾´ï³ÉµÄÈ«ÇòÕ½ÂÔºÏ×÷ÕýʽÉúЧ£¬½«¸ºÔðÔÚÖйúÉÌÒµ»¯°²¼Óά®£¨XGEVA®£©µØÊæµ¥¿¹×¢ÉäÒº¡¢KYPROLIS®×¢ÉäÓÿ¨·Ç×ôÃ×ºÍ BLINCYTO®×¢ÉäÓñ¶ÁÖÍ×Ī˫¿¹£¬²¢ºÏ×÷¿ª·¢20¿îÔÚÑеݲ½ø¿¹Ö×Áö¹ÜÏßÒ©Îï¡£°²½ø¹ºÈëÁËÔ¼28ÒÚÃÀÔªµÄ°Ù¼ÃÉñÖÝÃÀ¹ú´æÍйɣ¨ADS£©£¬Ô¼Îª¹«Ë¾20.5%µÄ¹É·Ý
  • Ðû²¼ÁËÓëEUSA PharmaÇ©Êð¾ÍÆä¹Â¶ùÉúÎïÖÆ¼ÁÒ©ÎïSYLVANT®£¨Ë¾Í×Îôµ¥¿¹£©ÔÚ´óÖлªµØÇøÒÔ¼° QARZIBA®?£¨dinutuximab beta£©ÔÚÖйú´ó½µÄ¶À¼Ò¿ª·¢ºÍÉÌÒµ»¯Ð­Òé
  • Ðû²¼ÁËÓëLeap Therapeutics¾ÍÆä¿¹Dickkopf-1£¨DKK1£©¿¹ÌåDKN-01ÔÚÑÇÖÞ£¨ÈÕ±¾³ýÍ⣩¡¢°Ä´óÀûÑǺÍÐÂÎ÷À¼µÄÁÙ´²¿ª·¢ºÍÉÌÒµ»¯´ï³É¶À¼ÒÑ¡ÔñȨºÍÊÚȨÐí¿ÉЭÒé

йڲ¡¶¾ÒßÇéÓ°ÏìÔ¤ÆÚ

  • ¹«Ë¾Ô¤¼Æ£¬Ð¹ڲ¡¶¾£¨COVID-19£©ÒßÇ齫¶Ô°üÀ¨ÉÌÒµÏúÊÛ¡¢Ò©Õþ¹µÍ¨ºÍ¼ì²é£¬ÒÔ¼°ÁÙ´²ÊÔÑ黼ÕßÕÐļÔÚÄÚµÄÖйúÒµÎñ´øÀ´Ò»¶¨µÄ¸ºÃæÓ°Ï죬ȡ¾öÓÚÒßÇéµÄ·¢Õ¹·¶Î§ºÍ³ÖÐøÊ±¼ä£¬¶Ô¹«Ë¾µÄÓ°ÏìÖ÷Òª½«ÔÚµÚÒ»¼¾¶Èµ«Ò²¿ÉÄܸü¾Ã¡£¹«Ë¾ÕýÔÚŬÁ¦¼õÉÙÒßÇéµ¼ÖµĹ¤×÷ÑÓ³ÙºÍÖжϣ¬¼ÌÐø°´ÕÕÔÚÖйúÖÆ¶¨µÄÁÙ´²¿ª·¢¡¢Ò©ÕþÊÂÎñÒÔ¼°ÉÌÒµ»¯Ä¿±ê¿ªÕ¹¹¤×÷¡£

2019ÄêµÚËļ¾¶ÈºÍÈ«Äê²ÆÎñÒµ¼¨

ÏÖ½ð¡¢ÏÖ½ðµÈ¼ÛÎï¡¢ÊÜÏÞ×ʽðºÍ¶ÌÆÚͶ×ʽØÖÁ2019Äê12ÔÂ31ÈÕΪ9.855ÒÚÃÀÔª£¬Ïà±È½Ï£¬2019Äê9ÔÂ30ÈյijÖÓжîΪ12.8ÒÚÃÀÔª£¬2018Äê12ÔÂ31ÈյijÖÓжîΪ18.1ÒÚÃÀÔª¡£½ØÖÁ2019Äê12ÔÂ31ÈÕµÄÏÖ½ðºÍÏÖ½ðµÈ¼ÛÎï²»°üÀ¨´Ó2020Äê1ÔÂ2ÈÕÕýʽÉúЧµÄ°²½øºÏ×÷ЭÒéÖÐÏòÆä³öÊÛADSËù»ñµÃµÄ28ÒÚÃÀÔª¡£

  • 2019ÄêµÚËļ¾¶ÈµÄÏÖ½ðºÍ¶ÌÆÚͶ×Ê×ܶî¼õÉÙÁË2.9109ÒÚÃÀÔª¡£¾­Óª»î¶¯ËùÓÃÏÖ½ðΪ2.6718ÒÚÃÀÔª¡£×ʱ¾Ö§³öΪ1546ÍòÃÀÔª£¬ÓÃÓÚÊÚȨЭÒéÔ¤¸¶¿îµÄÏÖ½ðΪ2000ÍòÃÀÔª¡£
  • ½ØÖÁ2019Äê12ÔÂ31ÈÕµÄÈ«ÄêµÄÏÖ½ðºÍ¶ÌÆÚͶ×ʼõÉÙÁË8.2372ÒÚÃÀÔª¡£¾­Óª»î¶¯ËùÓÃÏÖ½ðΪ7.5027ÒÚÃÀÔª¡£×ʱ¾Ö§³öΪ8961ÍòÃÀÔª£¬ÓÃÓÚÊÚȨЭÒéÔ¤¸¶¿îµÄÏÖ½ðΪ6900ÍòÃÀÔª¡£

ÊÕÈë½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄÊÕÈë·Ö±ðΪ5689ÍòÃÀÔªºÍ4.2821ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚÊÕÈë·Ö±ðΪ5867ÍòÃÀÔªºÍ1.9822ÒÚÃÀÔª¡£¼¾¶Èͬ±ÈÂÔÓмõÉÙÖ÷Òª¹éÒòÓÚÓëлù¹«Ë¾¹ØÓÚ°ÙÔó°²®ºÏ×÷ЭÒéÖÕÖ¹ºóȱÉÙºÏ×÷ÊÕÈ룬ÆäÖв¿·ÖÓëABRAXANE®¡¢Èð¸´ÃÀ®ºÍά´ïɯ®ÔÚ»ªµÄ²úÆ·ÊÕÈëÒÔ¼°BRUKINSA!"£¨Ôó²¼ÌæÄᣩÔÚÃÀµÄ²úÆ·ÊÕÈëµÄÔö¼ÓÏàµÖÏû¡£Äê¶Èͬ±ÈÔö¼ÓÖ÷Òª¹éÒòÓÚÓëлù¹«Ë¾£¨ÊôÓÚ°ÙʱÃÀÊ©¹ó±¦£©¾ÍÖÕÖ¹°ÙÔó°²®ºÏ×÷ЭÒé»ñµÃµÄ1.5ÒÚÃÀÔª£¬ÒÔ¼°²úÆ·ÊÕÈëµÄÔö¼Ó¡£

  • ½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄ²úÆ·ÊÕÈë·Ö±ðΪ5689ÍòÃÀÔªºÍ2.226ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚ²úÆ·ÊÕÈë·Ö±ðΪ3776ÍòÃÀÔªºÍ1.3089ÒÚÃÀÔª¡£
  • ½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄºÏ×÷ÊÕÈë·Ö±ðΪÁãºÍ2.0562ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄºÏ×÷ÊÕÈë·Ö±ðΪ2091ÍòÃÀÔªºÍ6743ÍòÃÀÔª¡£2019ÄêÈ«ÄêÊÕÈë°üÀ¨Óëлù¹«Ë¾¾ÍÖÕÖ¹°ÙÔó°²®ºÏ×÷Ëù»ñµÃµÄ1.5ÒÚÃÀÔª¡£

·ÑÓýØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄ·ÑÓ÷ֱðΪ4.4493ÒÚÃÀÔªºÍ13.9ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄ·ÑÓ÷ֱðΪ3.3948ÒÚÃÀÔªºÍ9.0399ÒÚÃÀÔª¡£

  • ÏúÊ۳ɱ¾½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄÏúÊ۳ɱ¾·Ö±ðΪ1798ÍòÃÀÔªºÍ7119ÍòÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄÏúÊ۳ɱ¾·Ö±ðΪ919ÍòÃÀÔªºÍ2871ÍòÃÀÔª¡£ÏúÊ۳ɱ¾ÓëÊÕ¹ºABRAXANE®¡¢Èð¸´ÃÀ®ºÍά´ïɯ®ÓÃÓÚÖйú·ÖÏúÓйء£
  • Ñз¢£¨R&D£©³É±¾½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄÑз¢³É±¾·Ö±ðΪ2.8326ÒÚÃÀÔªºÍ9.2734ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄÑз¢³É±¾·Ö±ðΪ2.5746ÒÚÃÀÔªºÍ6.7901ÒÚÃÀÔª¡£Ñз¢³É±¾µÄÔö¼ÓÖ÷Òª¹éÒòÓÚÔó²¼ÌæÄáºÍ°ÙÔó°²®¹Ø¼üÐÔÁÙ´²ÊÔÑé³ÖÐø½øÐеϼÕßÈë×éºÍÀ©Õ¹£¬ºóÆÚºòѡҩÎïµÄ×¢²áµÇ¼Ç£¬ÉÌÒµ»¯Ç°Éú²úºÍ¹©Ó¦£¬ÒÔ¼°ÁÙ´²Ç°ÏîÄ¿µÄÀ©Õ¹¡£Ñз¢·ÑÓõÄ×ÜÌåÔö¼Ó»¹¹éÒòÓÚÔ±¹¤¹ÉȨ½±ÀøÖ§³öµÄÔö¼Ó£¬½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄ¹ÉȨ½±ÀøÖ§³ö·Ö±ðΪ2169ÍòÃÀÔªºÍ7629ÍòÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄ¹ÉȨ½±ÀøÖ§³ö·Ö±ðΪ1609ÍòÃÀÔªºÍ5438ÍòÃÀÔª¡£¸ÃÔö¼ÓÖ÷ÒªÓÉÓÚÔ±¹¤ÈËÊýÔö¼ÓºÍ¹ÉƱ¼Û¸ñµÄÉÏÕÇ¡£
  • ÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ¹ÜÀí£¨SG&A£©·ÑÓýØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ¹ÜÀí·ÑÓ÷ֱðΪ1.4335ÒÚÃÀÔªºÍ3.8825ÒÚÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ¹ÜÀí·ÑÓ÷ֱðΪ7249ÍòÃÀÔªºÍ1.9539ÒÚÃÀÔª¡£ÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ¹ÜÀí·ÑÓõÄÔö¼ÓÖ÷Òª¹éÒòÓÚÔ±¹¤ÈËÊýµÄÔö¼Ó£¬°üÀ¨À©´óÉÌÒµÍŶӹæÄ£ÒÔÖ§³ÖÔÚ»ªºÍÔÚÃÀÉÏÊвúÆ·µÄ·ÖÏú£¬ÈÕÒæÔö¶àµÄÉÌÒµ»î¶¯ÒÔ¼°Ìá¸ßµÄרҵ·þÎñ·ÑºÍÔËÓª»î¶¯·¢Õ¹ËùÐè³É±¾µÄÔö¼Ó¡£ÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ¹ÜÀí·ÑÓõÄ×ÜÌåÔö¼Ó»¹ÓÉÓÚÓë´ËÏà¹ØµÄ¹ÉƱÆÚȨ·ÑÓõÄÔö¼Ó¡£½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄ¹ÉƱÆÚȨ·ÑÓ÷ֱðΪ1665ÍòÃÀÔªºÍ5786ÍòÃÀÔª£¬Ïà±È½Ï£¬2018ÄêͬÆÚµÄ¹ÉƱÆÚȨ·ÑÓ÷ֱðΪ987ÍòÃÀÔªºÍ3274ÍòÃÀÔª¡£¸ÃÔö¼ÓÖ÷ÒªÓÉÓÚÔ±¹¤ÈËÊýÔö¼ÓºÍ¹ÉƱ¼Û¸ñµÄÉÏÕÇ¡£
  • ¾»¿÷Ëð½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêµÄ¾»¿÷Ëð·Ö±ðΪ3.8806ÒÚÃÀÔªºÍ9.4863ÒÚÃÀÔª£¬»òÿ¹É0.49ÃÀÔªºÍ1.22ÃÀÔª£¬»òÿ¹ÉADS 6.39ÃÀÔªºÍ15.8ÃÀÔª£»Ïà±È½Ï£¬2018ÄêͬÆÚµÄ¾»¿÷Ëð·Ö±ðΪ2.6826ÒÚÃÀÔªºÍ6.7377ÒÚÃÀÔª£¬»òÿ¹É0.35ÃÀÔªºÍ0.93ÃÀÔª£¬»òÿ¹ÉADS 4.52ÃÀÔªºÍ12.15ÃÀÔª¡£

²ÆÎñÕªÒª

¼òÒªºÏ²¢×ʲú¸ºÕ®±íÕªÒªÊý¾Ý£¨ÃÀ¹úÒ»°ã¹«ÈÏ»á¼Æ×¼Ôò£©

£¨µ¥Î»Îª1,000ÃÀÔª£©

£¨¾­É󼯣©

½ØÖÁ

2019Äê

2018Äê

12ÔÂ31ÈÕ

12ÔÂ31ÈÕ

×ʲú£º

ÏÖ½ð¡¢ÏÖ½ðµÈ¼ÛÎï¡¢ÏÞÖÆÐÔÏÖ½ðºÍ¶ÌÆÚͶ×Ê [1]

$

985,503

$

1,809,222

Ó¦ÊÕÕË¿î

70,878

41,056

ÓªÔË×ʱ¾

862,384

1,697,390

¹Ì¶¨×ʲú¾»Öµ

242,402

157,061

×Ü×ʲú

$

1,612,289

$

2,249,684

¸ºÕ®ºÍËùÓÐÕßÈ¨Òæ£º

Ó¦¸¶ÕË¿î

$

122,488

$

113,283

Ó¦¼Æ·ÑÓü°ÆäËûÓ¦¸¶¿î

163,556

100,414

ÒøÐдû¿î

83,311

49,512

¹É¶«´û¿î

157,384

148,888

×ܸºÕ®

633,934

496,037

ÉÙÊý¹É¶«È¨Òæ

16,150

14,445

ËùÓÐÕßÈ¨ÒæºÏ¼Æ

$

978,355

$

1,753,647

[1] ½ØÖÁ2019Äê12ÔÂ31ÈÕµÄÏÖ½ð¡¢ÏÖ½ðµÈ¼ÛÎï¡¢ÊÜÏÞ×ʽðºÍ¶ÌÆÚͶ×ʲ»°üÀ¨´Ó2020Äê1ÔÂ2ÈÕÕýʽÉúЧµÄ°²½øºÏ×÷ЭÒéÖлñµÃµÄ28ÒÚÃÀÔª¡£

¼òÒªºÏ²¢ÓªÔ˱¨±í£¨ÃÀ¹úÒ»°ã¹«ÈÏ»á¼Æ×¼Ôò£©

£¨³ýÆÕͨ¹ÉÊýÁ¿¡¢ADS ÊýÁ¿¡¢Ã¿¹ÉÆÕͨ¹ÉºÍÿ¹ÉADS Êý¾ÝÍ⣬µ¥Î»Îª1,000 ÃÀÔª£©

½ØÖÁ12ÔÂ31ÈÕµÄ3¸öÔÂ

½ØÖÁ12ÔÂ31ÈÕµÄ12¸öÔÂ

2019

2018

2019

2018

£¨Î´¾­É󼯣©

£¨¾­É󼯣©

ÊÕÈ룺

²úÆ·ÊÕÈë¾»¶î

$

56,892

$

37,762

$

222,596

$

130,885

ºÏ×÷ÊÕÈë

¡ª

20,908

205,616

67,335

×ÜÊÕÈë

56,892

58,670

428,212

198,220

·ÑÓãº

²úÆ·ÏúÊ۳ɱ¾

(17,984)

(9,193)

(71,190)

(28,705)

Ñз¢·ÑÓà [1]

(283,259)

(257,464)

(927,338)

(679,005)

ÏúÊÛ¡¢Ò»°ã¼°ÐÐÕþ·ÑÓÃ

(143,354)

(72,490)

(388,249)

(195,385)

ÎÞÐÎ×ʲú̯Ïú

(332)

(331)

(1,326)

(894)

·ÑÓÃ×ܼÆ

(444,929)

(339,478)

(1,388,103)

(903,989)

ÓªÔËËðʧ

(388,037)

(280,808)

(959,891)

(705,769)

ÀûÏ¢ÊÕÈ루·ÑÓ㩾»Öµ

(438)

5,950

9,131

13,947

ÆäËûÊÕÈ루·ÑÓ㩾»Öµ

8,141

(396)

7,174

1,993

˰ǰËðʧ

(380,334)

(275,254)

(943,586)

(689,829)

ËùµÃ˰£¨·ÑÓã©ÊÕÒæ

(7,561)

8,544

(6,992)

15,796

¾»¿÷Ëð

(387,895)

(266,710)

(950,578)

(674,033)

¼õ£º¹éÊôÓÚÉÙÊý¹É¶«È¨ÒæµÄ¾»ÊÕÒæ£¨Ëðʧ£©

166

1,545

(1,950)

(264)

¹éÊôÓÚ°Ù¼ÃÉñÖݵľ»¿÷Ëð

$

(388,061)

$

(268,255)

$

(948,628)

$

(673,769)

¹éÊôÓÚ°Ù¼ÃÉñÖݵÄÿ¹É¾»¿÷Ë𣬻ù±¾ºÍÏ¡Êͺó

$

(0.49)

$

(0.35)

$

(1.22)

$

(0.93)

ÓÃÓÚ¼ÆËãÿ¹ÉÆÕͨ¹É¾»ËðʧµÄ¼ÓȨƽ¾ùÊý£¬»ù±¾ºÍÏ¡Êͺó

788,899,247

771,982,215

780,701,283

720,753,819

ÿ¹ÉADS¹éÊôÓÚ°Ù¼ÃÉñÖݵľ»¿÷Ë𣬻ù±¾ºÍÏ¡Êͺó

$

(6.39)

$

(4.52)

$

(15.80)

$

(12.15)

ÓÃÓÚ¼ÆËãÿ¹ÉADS¾»ËðʧµÄADS¼ÓȨƽ¾ùÊý£¬»ù±¾ºÍÏ¡Êͺó

60,684,557

59,383,247

60,053,945

55,442,601

[1] ½ØÖÁ2019Äê12ÔÂ31ÈյĵÚËļ¾¶ÈºÍÈ«ÄêÑз¢·ÑÓðüÀ¨ÓÃÓÚÕýÔÚ¿ªÕ¹µÄÑз¢ºÏ×÷µÄ·ÑÓ㬷ֱðΪ2000ÍòÃÀÔªºÍ5000ÍòÃÀÔª¡£

¹ØÓÚ°Ù¼ÃÉñÖÝ

°Ù¼ÃÉñÖÝÊÇÒ»¼ÒÈ«ÇòÐԵġ¢ÉÌÒµ½×¶ÎµÄ¡¢ÒÔÑз¢Îª»ù´¡µÄÉúÎï¿Æ¼¼¹«Ë¾£¬×¨×¢ÓÚ·Ö×Ó°ÐÏòºÍÃâÒßÖ×ÁöÁÆ·¨µÄÑз¢¡£°Ù¼ÃÉñÖÝĿǰÔÚÖйú´ó½¡¢ÃÀ¹ú¡¢°Ä´óÀûÑǺÍÅ·ÖÞÓµÓÐ3500 ¶àÃûÔ±¹¤£¬ÔÚÑвúÆ·Ïß°üÀ¨ÐÂÐͿڷþС·Ö×ÓÀàºÍµ¥¿Ë¡¿¹ÌåÀ࿹°©Ò©Îï¡£°Ù¼ÃÉñÖÝĿǰҲÕýÔÚ´òÔ쿹°©ÖÎÁƵÄÒ©Îï×éºÏ·½°¸£¬Ö¼ÔÚΪ°©Ö¢»¼ÕßµÄÉú»î´øÀ´³ÖÐø¡¢ÉîÔ¶µÄÓ°Ïì¡£°Ù¼ÃÉñÖÝÔÚÃÀ¹úÏúÊÛÆä×ÔÖ÷Ñз¢µÄBTK ÒÖÖÆ¼ÁBRUKINSA!"£¨Ôó²¼ÌæÄᣩ£»ÔÚÖйú£¬Æä¿¹PD1 ¿¹ÌåÒ©Îï°ÙÔó°²®£¨ÌæÀ×ÀûÖéµ¥¿¹£©ÒѾ­»ñµÃÉÏÊÐÅú×¼¡£ÔÚлùÎïÁ÷ÓÐÏÞÔðÈι«Ë¾£¨ÊôÓÚ°ÙʱÃÀÊ©¹ó±¦¹«Ë¾£©µÄÊÚȨÏ£¬°Ù¼ÃÉñÖÝÔÚ»ªÏúÊÛABRAXANE®×¢ÉäÓÃ×Ïɼ´¼£¨°×µ°°×½áºÏÐÍ£©¡¢Èð¸´ÃÀ®£¨À´ÄǶȰ·£©ºÍά´ïɯ®£¨×¢ÉäÓð¢Ôú°ûÜÕ£©[i]£»ÔÚ°²½ø¹«Ë¾µÄÊÚȨÏ£¬°Ù¼ÃÉñÖݼƻ®ÔÚ»ªÏúÊÛ°²¼Óά®£¨XGEVA®£©µØÊæµ¥¿¹×¢ÉäÒº[ii]¡£ÓûÁ˽â¸ü¶àÐÅÏ¢£¬Çë·ÃÎÊwww.beigene.cn¡£

ǰհÐÔÉùÃ÷

±¾ÐÂΟå°üº¬¸ù¾Ý¡¶1995 Äê˽ÈË֤ȯËßËϸĸ﷨°¸¡·£¨Private Securities Litigation Reform Act of 1995£©ÒÔ¼°ÆäËûÁª°î֤ȯ·¨ÂÉÖж¨ÒåµÄǰհÐÔÉùÃ÷¡£°üÀ¨ÓйذټÃÉñÖݺòѡҩÎïÁîÈ˹ÄÎèµÄÁÙ´²Êý¾Ý¡¢±¾¹«Ë¾Ò©Îï²úÆ·ÊÕÈë¡¢ºóÆÚÁÙ´²ÊÔÑéºÍÔ¤¼ÆÊý¾Ý¹«²¼¡¢±¾¹«Ë¾Ò©ÎïºòÑ¡ÎïµÄÔ¤¼ÆµÄÉÌÒµ·¢²¼¡¢Ô¤ÆÚµÄÁÙ´²¿ª·¢¼Æ»®¡¢Ò©Õþ×¢²áÀï³Ì±®ºÍÉÌÒµ»¯½ø³Ì¡¢Ð¹ڲ¡¶¾¶Ô¹«Ë¾ÁÙ´²¿ª·¢¡¢ÉÌÒµÒÔ¼°ÆäËûÒµÎñÔËÓª´øÀ´µÄÓ°Ï죬ÒÔ¼°¡°½üÆÚÒµÎñÁÁµãºÍÔ¤¼ÆÀï³Ì±®Ê¼þ¡±±êÌâϵı¾¹«Ë¾µÄ¼Æ»®¼°Ô¤ÆÚµÄÀï³Ì±®Ê¼þ¡£ÓÉÓÚ¸÷ÖÖÖØÒªÒòËØµÄÓ°Ï죬ʵ¼Ê½á¹û¿ÉÄÜÓëǰհÐÔÉùÃ÷ÓÐÖØ´ó²îÒì¡£ÕâЩÒòËØ°üÀ¨ÁËÒÔÏÂÊÂÏîµÄ·çÏÕ£º°Ù¼ÃÉñÖÝÖ¤Ã÷ÆäºòѡҩÎ﹦ЧºÍ°²È«ÐÔµÄÄÜÁ¦£»ºòѡҩÎïµÄÁÙ´²½á¹û¿ÉÄܲ»Ö§³Ö½øÒ»²½¿ª·¢»òÉÏÊÐÉóÅú£»Ò©Õþ²¿ÃŵÄÐж¯¿ÉÄÜ»áÓ°Ïìµ½ÁÙ´²ÊÔÑéµÄÆô¶¯¡¢Ê±¼ä±íºÍ½øÕ¹ÒÔ¼°²úÆ·ÉÏÊÐÉóÅú£»°Ù¼ÃÉñÖݵÄÉÏÊвúÆ·¼°Ò©ÎïºòÑ¡ÎÈçÄÜ»ñÅú£©»ñµÃÉÌÒµ³É¹¦µÄÄÜÁ¦£»°Ù¼ÃÉñÖÝ¶ÔÆä¼¼ÊõºÍÒ©Îï֪ʶ²úȨ±£»¤»ñµÃºÍά»¤µÄÄÜÁ¦£»°Ù¼ÃÉñÖÝÒÀÀµµÚÈý·½½øÐÐÒ©Î↑·¢¡¢Éú²úºÍÆäËû·þÎñµÄÇé¿ö£»°Ù¼ÃÉñÖÝÓÐÏÞµÄÓªÔËÀúÊ·ºÍ»ñµÃ½øÒ»²½µÄÓªÔË×ʽðÒÔÍê³ÉºòѡҩÎ↑·¢ºÍÉÌÒµ»¯µÄÄÜÁ¦£»Ð¹ڲ¡¶¾¶Ô¹«Ë¾ÁÙ´²¿ª·¢¡¢ÉÌÒµÒÔ¼°ÆäËûÒµÎñÔËÓª´øÀ´µÄÓ°Ï죻ÒÔ¼°°Ù¼ÃÉñÖÝÔÚ×î½ü¼¾¶È±¨¸æµÄ10-Q ±í¸ñÖС°·çÏÕÒòËØ¡±Õ½ÚÀï¸üÈ«ÃæÌÖÂ۵ĸ÷Àà·çÏÕ£»ÒÔ¼°°Ù¼ÃÉñÖÝÏòÃÀ¹ú֤ȯ½»Ò×ίԱ»áÆÚºó³Ê±¨ÖйØÓÚDZÔÚ·çÏÕ¡¢²»È·¶¨ÐÔÒÔ¼°ÆäËûÖØÒªÒòËØµÄÌÖÂÛ¡£±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟ巢²¼Ö®ÈÕ£¬³ý·Ç·¨ÂÉÒªÇ󣬰ټÃÉñÖݲ¢ÎÞÔðÈθüиÃЩÐÅÏ¢¡£


[i] ABRAXANE®Îª Abraxis ÓÐÏÞÔðÈι«Ë¾£¨ÊôÓÚ°ÙʱÃÀÊ©¹ó±¦¹«Ë¾£©×¢²áÉ̱ꣻÈð¸´ÃÀ®ºÍά´ïɯ®ÎªÐ»ùÒ½Ò©¹«Ë¾£¨ÊôÓÚ°ÙʱÃÀÊ©¹ó±¦¹«Ë¾£©µÄ×¢²áÉ̱ꡣ

[ii] °²¼Óά®£¨XGEVA®£©Îª°²½ø¹«Ë¾µÄ×¢²áÉ̱ꡣ

Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ